Key result
Ablation of oxidized CaMKII fully prevents LVEF decline in sleep apnea mouse models.
Why the study?
Studies describing CaMKII-dependent Ca homeostasis dysregulation in sleep-disordered breathing only partly explain the mechanism and are limited by patient heterogeneity.
Does genetic ablation of oxidative CaMKII activation prevent contractile dysfunction and pro-arrhythmic activity in a mouse model of obstructive sleep apnea?
Does genetic ablation of oxidative CaMKII activation prevent contractile dysfunction and pro-arrhythmic activity in a mouse model of obstructive sleep apnea?
Absolute Event Rate: 51.42% vs 55.5%
p-value: p=<0.001
In a mouse model of obstructive sleep apnea, genetic ablation of the oxidative activation sites of CaMKII prevented OSA-induced contractile dysfunction and pro-arrhythmic activity.
Oxidative CaMKII ablation protects against OSA-induced LV dysfunction in mice; leaves open translation to human sleep-disordered breathing therapies.
Left ventricular contractile dysfunction and arrhythmias frequently occur in patients with sleep-disordered breathing (SDB). The CaMKII-dependent dysregulation of cellular Ca homeostasis has recently been described in SDB patients, but these studies only partly explain the mechanism and are limited by the patients' heterogeneity. Here, we analyzed contractile function and Ca homeostasis in a mouse model of obstructive sleep apnea (OSA) that is not limited by confounding comorbidities. OSA was induced by artificial tongue enlargement with polytetrafluorethylene (PTFE) injection into the tongue of wildtype mice and mice with a genetic ablation of the oxidative activation sites of CaMKII (MMVV knock-in). After eight weeks, cardiac function was assessed with echocardiography. Reactive oxygen species (ROS) and Ca transients were measured using confocal and epifluorescence microscopy, respectively. Wildtype PTFE mice exhibited an impaired ejection fraction, while MMVV PTFE mice were fully protected. As expected, isolated cardiomyocytes from PTFE mice showed increased ROS production. We further observed decreased levels of steady-state Ca transients, decreased levels of caffeine-induced Ca transients, and increased pro-arrhythmic activity (defined as deviations from the diastolic Ca baseline) only in wildtype but not in MMVV PTFE mice. In summary, in the absence of any comorbidities, OSA was associated with contractile dysfunction and pro-arrhythmic activity and the inhibition of the oxidative activation of CaMKII conveyed cardioprotection, which may have therapeutic implications.
No takes yet. Share an insight, caveat, or question.
Hegner et al. (2023) studied Obstructive Sleep Apnea (OSA). PTFE injection into the tongue (OSA induction) vs. Control (CTRL) group was evaluated on Left ventricular ejection fraction at 8 weeks (p=<0.001). In a mouse model of obstructive sleep apnea, wildtype mice exhibited a significant decrease in left ventricular ejection fraction to 51.42% at 8 weeks, whereas mice with genetic ablation of the oxidative activation sites of CaMKII were fully protected.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: